Junshi Biosciences Completes First Patient Dosing in Phase 3 JS203 Trial
Junshi Biosciences said the first patient has been dosed in a Phase 3 trial of JS203 combined with chemotherapy for diffuse large B-cell lymphoma.
Story updates
03:34:13 AM UTC
SquawkNews
Shanghai Junshi Biosciences dosed the first patient in a randomized, open-label Phase 3 study of JS203 plus chemotherapy vs rituximab plus chemotherapy in relapsed/refractory DLBCL. The 282-subject trial uses overall survival as the primary endpoint.Material DetailsContext by AI AnalystThis is an e…